| DC7191 |
LY-2940680(Taladegib)
Featured
|
LY2940680 binds to the Smoothened (Smo) receptor and potently inhibits Hedgehog (Hh) signaling. |
|
| DC8344 |
LY3009120
Featured
|
LY3009120 is a potent and selective pan-RAF inhibitor with potential anticancer activity. |
|
| DC10219 |
LY3023414
Featured
|
LY3023414 is an oral ATP competitive inhibitor of the class I PI3K isoforms, mTOR and DNA-PK. |
|
| DC7776 |
LY-3039478 |
LY3039478 a orally bioavailable, novel small molecule Notch inhibitor with an IC50 of ~1nM in most of the tumor cell lines tested. |
|
| DC10675 |
LY3200882
Featured
|
LY3200882 is a novel, highly selective TGFβRI small molecule inhibitor. |
|
| DC10640 |
LY3214996
Featured
|
LY3214996 is a selective and novel ERK1/2 inhibitor with IC50 of 5 nM for both enzymes in biochemical assays. It potently inhibits cellular phospho-RSK1 in BRAF and RAS mutant cancer cell lines. |
|
| DC12261 |
LY3295668 (AK-01) |
LY3295668 is a potent, orally active and highly specific Aurora-A kinase inhibitor, with Ki values of 0.8 nM and 1038 nM for AurA and AurB, respectively. |
|
| DC2018 |
LY335979 (Zosuquidar 3HCl)
Featured
|
LY335979 (Zosuquidar) is a potent modulator of P-glycoprotein-mediated multidrug resistance with Ki of 60 nM. |
|
| DC10560 |
MAK683
Featured
|
MAK683 is a novel PRC2/EED inhibitor. |
|
| DC8031 |
Marimastat |
Marimastat is a broad spectrum MMP inhibitor and selective TACE inhibitor |
|
| DC7460 |
Masitinib
Featured
|
Masitinib is a broad coronavirus 3CL inhibitor that effectively blocks replication of SARS-CoV-2. Science 20 Jul 2021: eabg5827 DOI: 10.1126/science.abg5827 |
|
| DC5069 |
Enzalutamide (MDV3100)
Featured
|
MDV3100 is an androgen-receptor (AR) antagonist with IC50 of 36 nM. |
|
| DC9050 |
Melphalan
Featured
|
Melphalan(Sarcolysin; L-PAM) is a chemotherapy drug belonging to the class of nitrogen mustard alkylating agents; attaches the alkyl group to the guanine base of DNA. |
|
| DC4182 |
Temozolomide
Featured
|
Methazolastone (Temozolomide, Temodar, Temodal) is a DNA damage inducer. |
|
| DCAPI1146 |
Methoxsalen (Oxsoralen) |
Methoxsalen (Oxsoralen) |
|
| DC7196 |
MGCD0103 (Mocetinostat)
Featured
|
MGCD0103 (Mocetinostat) is a potent HDAC inhibitor with IC50 of 0.15, 0.29 and 1.66 μM for HDAC 1, HDAC 2 and HDAC 3, respectively. |
|
| DC8545 |
MI-503
Featured
|
MI-503 is a highly potent and orally bioavailable small molecule inhibitor of the menin-MLL interaction. |
|
| DC8414 |
MI-77301 (SAR405838)
Featured
|
MI-77301 (SAR405838) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1. |
|
| DC9836 |
Mivebresib(ABBV-075）
Featured
|
Mivebresib is a novel BET family inhibitor, disrupts critical transcription programs that drive prostate cancer growth to induce potent anti-tumor activity in vitro and in vivo. |
|
| DC1070 |
MK-1775(AZD-1775,Adavosertib)
Featured
|
MK-1775 is a potent and selective Wee1 inhibitor with IC50 of 5.2 nM. |
|
| DC7465 |
MK-2206 2HCl
Featured
|
MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2. |
|
| DC8479 |
MK-2461 |
MK-2461 is a potent, multi-targeted inhibitor for c-Met(WT/mutants) with IC50 of 0.4-2.5 nM, less potent to Ron, Flt1; 8- to 30-fold greater selectivity of c-Met targets versus FGFR1, FGFR2, FGFR3, PDGFRβ, KDR, Flt3, Flt4, TrkA, and TrkB. |
|
| DC9707 |
MK-4101
Featured
|
MK-4101 is a potent SMO Inhibitor of the Hedgehog Pathway, highly active against Medulloblastoma and Basal Cell Carcinoma. |
|
| DC4179 |
Niraparib(MK4827) free base
Featured
|
MK-4827 is an inhibitor of poly (ADP-ribose) polymerase (PARP) with potential antineoplastic activity. |
|
| DC9862 |
Niraparib(MK4827) hydrochloride
Featured
|
MK-4827 is an inhibitor of poly (ADP-ribose) polymerase (PARP) with potential antineoplastic activity. |
|
| DC9576 |
Niraparib tosylate
Featured
|
MK-4827(Niraparib) tosylate is a selective inhibitor of PARP1/PARP2 with IC50 of 3.8 nM/2.1 nM; with great activity in cancer cells with mutant BRCA-1 and BRCA-2; >330-fold selective against PARP3, V-PARP and Tank1.
|
|
| DC7466 |
MK-5108 |
MK-5108 (VX-689) is a highly selective Aurora A inhibitor with IC50 of 0.064 nM; 220- and 190-fold more selective for Aurora A than Aurora B/C. |
|
| DC9682 |
ML-264
Featured
|
ML264 is a novel small molecule inhibitor of Krüppel-like factor 5 (KLF5). |
|
| DC10282 |
ML385
Featured
|
ML385 is a novel and specific NRF2 inhibitor. |
|
| DC5086 |
Ixazomib(MLN2238)
Featured
|
MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31 and 3500 nM. |
|
